Menstruation and Aspirin Use
For menstruating women requiring low-dose aspirin for cardiovascular prevention, continue aspirin therapy as indicated by cardiovascular risk—menstrual bleeding is not increased by low-dose aspirin, and for menstrual pain relief, use acetaminophen or ibuprofen rather than aspirin.
Aspirin and Menstrual Bleeding: The Evidence
The concern about aspirin increasing menstrual bleeding is not supported by research evidence. A well-designed study specifically examining 81 mg daily aspirin in 915 women found no significant differences in menstrual cycle length, follicular phase, luteal phase, or hormone levels compared to placebo 1. Additionally, a 1985 study demonstrated that aspirin at 325 mg every 4 hours during the first 24 hours of menstruation did not alter total menstrual loss or the pattern of bleeding 2.
This is clinically important: the bleeding risk from aspirin is primarily gastrointestinal and intracranial, not menstrual. The FDA label warns about stomach bleeding risk, particularly in those over 60, with history of ulcers, or taking other NSAIDs 3, but does not identify menstrual bleeding as a concern.
When to Use Aspirin in Menstruating Women
Primary Prevention
The decision framework depends on age and cardiovascular risk:
For women aged 40-59 years:
- Use aspirin 75-100 mg daily if 10-year cardiovascular disease risk ≥10% 4, 5
- The benefit is primarily stroke reduction (24% reduction in ischemic stroke) 4
- Number needed to treat is 5,000 to prevent one stroke per year 4
- This is a shared decision weighing small cardiovascular benefit against bleeding risk
For women ≥65 years:
- Aspirin shows more consistent benefit with 26% reduction in major cardiovascular events and 30% reduction in ischemic stroke 4
- Consider aspirin if blood pressure is controlled and cardiovascular benefit outweighs gastrointestinal/hemorrhagic stroke risk 4
For women ≥60 years (updated guidance):
- Do not initiate aspirin for primary prevention—the 2022 USPSTF recommends against starting aspirin at age 60 or older 6
- No net benefit demonstrated in this age group
Do NOT use aspirin for primary prevention in:
- Women at low cardiovascular risk 4
- Women with diabetes alone without established cardiovascular disease 4, 7
Secondary Prevention
For women with established cardiovascular disease (prior MI, stroke, or known atherosclerotic disease), aspirin 75-100 mg daily is strongly recommended regardless of menstrual status 8, 9. The benefit clearly outweighs bleeding risk in this population.
Analgesics for Menstrual Pain
For menstrual cramps and pain, use acetaminophen or ibuprofen—not aspirin.
The evidence shows:
- Both aspirin and acetaminophen at 650 mg every 4 hours effectively reduce menstrual cramps compared to placebo 2
- However, acetaminophen does not increase bleeding risk and is the preferred first-line agent
- Ibuprofen and other NSAIDs are also effective for dysmenorrhea but carry similar gastrointestinal bleeding risks as aspirin when used regularly 10
Practical approach for menstrual pain:
- First-line: Acetaminophen 325-650 mg every 4-6 hours as needed
- Second-line: Ibuprofen 200-400 mg every 4-6 hours if acetaminophen insufficient
- Avoid: Regular aspirin use specifically for menstrual pain (though continuing cardiovascular-indicated aspirin is safe)
Critical Caveats
Bleeding risk factors to assess:
- Age >60 years (doubles gastrointestinal bleeding risk) 5
- History of gastrointestinal ulcers (2-3 times higher bleeding risk) 5
- Concurrent NSAID use (quadruples bleeding risk) 5
- Uncontrolled hypertension 5
- Anticoagulant use 5
- Anemia or renal disease 7
The absolute bleeding risk: Aspirin increases major gastrointestinal bleeding by approximately 0.01% per year (number needed to harm: 10,000) 4. In real-world settings, this may be as high as 5 per 1,000 per year 7.
Dosing: Use 75-100 mg daily (81 mg tablets are standard in the US). Higher doses do not provide additional cardiovascular benefit but increase bleeding risk 11, 5, 8.
Common pitfall: Do not discontinue appropriately indicated aspirin due to concerns about menstrual bleeding—the evidence does not support this concern. However, do reassess the indication annually, particularly as women age past 60 years when primary prevention benefits diminish 6, 12.